ZBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Zenas BioPharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$26.71+1.87 (+7.53%)
Close on Oct 19, 2026
- Market cap
- $1.69B
- P/E (TTM)
- –
- Dividend yield
- –
Zenas BioPharma, Inc. revenue by segment
By business segment
By product or service
By region
From the segment and revenue-disaggregation notes of Zenas BioPharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.